JP2017524005A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524005A5
JP2017524005A5 JP2017506968A JP2017506968A JP2017524005A5 JP 2017524005 A5 JP2017524005 A5 JP 2017524005A5 JP 2017506968 A JP2017506968 A JP 2017506968A JP 2017506968 A JP2017506968 A JP 2017506968A JP 2017524005 A5 JP2017524005 A5 JP 2017524005A5
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
compound
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017506968A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663909B2 (ja
JP2017524005A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/044974 external-priority patent/WO2016025669A1/en
Publication of JP2017524005A publication Critical patent/JP2017524005A/ja
Publication of JP2017524005A5 publication Critical patent/JP2017524005A5/ja
Application granted granted Critical
Publication of JP6663909B2 publication Critical patent/JP6663909B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017506968A 2014-08-13 2015-08-13 オレキシンレセプターモジュレーターとしてのジフルオロピロリジン Active JP6663909B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462037024P 2014-08-13 2014-08-13
US62/037,024 2014-08-13
PCT/US2015/044974 WO2016025669A1 (en) 2014-08-13 2015-08-13 Difluoropyrrolidines as orexin receptor modulators

Publications (3)

Publication Number Publication Date
JP2017524005A JP2017524005A (ja) 2017-08-24
JP2017524005A5 true JP2017524005A5 (enExample) 2018-09-20
JP6663909B2 JP6663909B2 (ja) 2020-03-13

Family

ID=55304607

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017506968A Active JP6663909B2 (ja) 2014-08-13 2015-08-13 オレキシンレセプターモジュレーターとしてのジフルオロピロリジン

Country Status (8)

Country Link
US (1) US10221170B2 (enExample)
EP (1) EP3180332B1 (enExample)
JP (1) JP6663909B2 (enExample)
AR (1) AR101558A1 (enExample)
ES (1) ES2901418T3 (enExample)
TW (1) TW201613902A (enExample)
UY (1) UY36272A (enExample)
WO (1) WO2016025669A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
HRP20220642T1 (hr) 2016-03-10 2022-06-24 Janssen Pharmaceutica Nv Postupci za liječenje depresije uporabom antagonista receptora oreksina 2
CN106278918B (zh) * 2016-08-12 2018-05-11 合肥久诺医药科技有限公司 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法
JP7012703B2 (ja) * 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
EP3594203B1 (en) 2017-03-08 2021-08-04 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
JP6574918B1 (ja) 2017-08-03 2019-09-11 武田薬品工業株式会社 複素環化合物およびその用途
JP7189140B2 (ja) 2017-08-03 2022-12-13 武田薬品工業株式会社 複素環化合物およびその用途
JP6874217B2 (ja) * 2017-09-28 2021-05-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なｎ−（２，２−ジフルオロエチル）−ｎ−［（ピリミジニルアミノ）プロパニル］アリールカルボキサミド
JP7413261B2 (ja) 2018-06-29 2024-01-15 武田薬品工業株式会社 複素環化合物およびその用途
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US12091410B2 (en) 2018-12-12 2024-09-17 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
CN118271298A (zh) * 2019-01-31 2024-07-02 武田药品工业株式会社 杂环化合物及其用途
US11339673B2 (en) 2020-01-17 2022-05-24 Raytheon Technologies Corporation Rotor assembly with internal vanes
US11371351B2 (en) 2020-01-17 2022-06-28 Raytheon Technologies Corporation Multi-disk bladed rotor assembly for rotational equipment
US11434771B2 (en) 2020-01-17 2022-09-06 Raytheon Technologies Corporation Rotor blade pair for rotational equipment
US11208892B2 (en) 2020-01-17 2021-12-28 Raytheon Technologies Corporation Rotor assembly with multiple rotor disks
US11286781B2 (en) 2020-01-17 2022-03-29 Raytheon Technologies Corporation Multi-disk bladed rotor assembly for rotational equipment
US11401814B2 (en) 2020-01-17 2022-08-02 Raytheon Technologies Corporation Rotor assembly with internal vanes
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5049578A (en) 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
CA2331735A1 (en) 1998-05-08 1999-11-18 Smithkline Beecham P.L.C. Phenylurea and phenylthio urea derivatives
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
US6699879B1 (en) 1999-02-12 2004-03-02 Smithkline Beecham P.L.C. Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
JP2002536447A (ja) 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニル尿素およびフェニルチオ尿素誘導体
AU5283800A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
CA2408343A1 (en) 2000-05-11 2002-11-07 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
EP1353918B1 (en) 2000-11-28 2005-01-12 Smithkline Beecham Plc Morpholine derivatives as antagonists of orexin receptors
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
CZ20032990A3 (cs) * 2001-05-05 2004-04-14 Smithkline Beecham P. L. C. N-aroylové cyklické aminy
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
MXPA04002269A (es) 2002-07-09 2004-06-29 Actelion Pharmaceuticals Ltd Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona.
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
BR0315115A (pt) 2002-10-11 2005-08-16 Actelion Pharmaceuticals Ltd Compostos, composições farmacêuticas, método para tratar ou prevenir doenças ou distúrbios em que se requer um antagonista de receptores de orexina humana, processo para a fabricação de composições farmacêuticas, e, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
WO2004052876A1 (en) 2002-12-12 2004-06-24 Janssen Pharmaceutica, N.V. Substituted 4-phenyl-[1,3]-dioxanes
AU2004224156B2 (en) 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
ES2297413T3 (es) 2003-04-28 2008-05-01 Actelion Pharmaceuticals Ltd. Derivados de quinoxalinona-3-ona utilizados como antagonistas del receptor de orexina.
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DE602004023516D1 (de) 2003-08-07 2009-11-19 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
JP4094050B2 (ja) 2004-03-01 2008-06-04 アクテリオン ファーマシューティカルズ リミテッド 置換１，２，３，４−テトラヒドロイソキノリン誘導体
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
AU2006235302A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
US7968289B2 (en) 2005-05-03 2011-06-28 Ensemble Therapeutics Corporation Turn over probes and use thereof for nucleic acid detection
EP1888563A1 (en) 2005-05-23 2008-02-20 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
CA2617324A1 (en) 2005-08-04 2007-02-15 Merck & Co., Inc. Aminoethane sulfonamide orexin receptor antagonists
US20090176789A1 (en) 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
CA2629192A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
CN101009515A (zh) 2006-01-24 2007-08-01 华为技术有限公司 通信终端设备管理方法及通信终端
TW200800020A (en) 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
US20090105318A1 (en) 2006-03-29 2009-04-23 Coleman Paul J Amidoethylthioether Orexin Receptor Antagonists
CN101460453B (zh) 2006-04-11 2012-10-03 埃科特莱茵药品有限公司 磺酰胺化合物
ATE496051T1 (de) 2006-04-26 2011-02-15 Actelion Pharmaceuticals Ltd Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
WO2007143813A1 (en) 2006-06-16 2007-12-21 Husky Injection Molding Systems Ltd. Preventative maintenance update system
CA2657552A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. Substituted diazepan orexin receptor antagonists
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
AU2007272795A1 (en) 2006-07-14 2008-01-17 Merck & Co., Inc. 2-substituted proline bis-amide orexin receptor antagonists
CA2659299A1 (en) 2006-08-15 2008-02-21 Actelion Pharmaceuticals Ltd Azetidine compounds
WO2008026149A1 (en) 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
CL2007002809A1 (es) 2006-09-29 2008-04-18 Actelion Pharmaceuticals Ltd Compuestos derivados de 3-aza biciclo [3.1.0]hexano; y su uso en el tratamiento de enfermedades tales como desordenes psicoticos y de ansiedad, desordenes del sueno, uso y abuso de sustancias psicoactivas, demencia y deterioro de funciones cognitivas
US8133901B2 (en) 2006-12-01 2012-03-13 Actelion Pharmaceuticals Ltd. 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
ES2380391T3 (es) 2006-12-22 2012-05-11 Actelion Pharmaceuticals Ltd. Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina
TW200833328A (en) 2006-12-28 2008-08-16 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.1.0]hexane derivatives
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
EP2131654A4 (en) 2007-03-02 2011-02-02 Merck Sharp & Dohme Bipyridine-carboxamide-orexin receptor Antagonist
AU2008223916A1 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
DE602008006368D1 (de) 2007-03-15 2011-06-01 Hoffmann La Roche Malonamide als orexin-antagonisten
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ES2365444T3 (es) 2007-04-04 2011-10-05 F. Hoffmann-La Roche Ag Heterociclos como antagonistas de orexina.
ES2351079T3 (es) 2007-05-14 2011-01-31 Actelion Pharmaceuticals Ltd. Derivados de 2-ciclopropil-tiazol.
JP2010527924A (ja) 2007-05-18 2010-08-19 メルク・シャープ・エンド・ドーム・コーポレイション オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
WO2008147518A1 (en) 2007-05-23 2008-12-04 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
JP2010531871A (ja) 2007-07-03 2010-09-30 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．３．０］オクタン化合物
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
EP2185512B1 (en) 2007-07-27 2010-12-29 Actelion Pharmaceuticals Ltd. Trans-3-aza-bicyclo[3.1.0]hexane derivatives
WO2009016087A1 (en) 2007-08-02 2009-02-05 F. Hoffmann-La Roche Ag Monoamide derivatives as orexin receptor antagonists
CA2695621A1 (en) 2007-08-09 2009-02-12 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
BRPI0814149A2 (pt) 2007-08-10 2011-09-13 Cortex Pharma Inc composto, composição farmacêutica, métodos de tratamento e uso do composto
BRPI0815079A2 (pt) 2007-08-15 2015-02-03 Actelion Pharmaceuticals Ltd Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CA2699328A1 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
JP2011502146A (ja) 2007-10-29 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 置換ジアゼパンオレキシン受容体アンタゴニスト
WO2009079637A1 (en) 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
CA2705411A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
CA2709050C (en) 2008-01-21 2016-06-14 F. Hoffmann-La Roche Ag Sulfonamides as orexin antagonists
ES2367341T3 (es) 2008-02-12 2011-11-02 F. Hoffmann-La Roche Ag Derivados de piperidina-sulfonamida.
BRPI0908096A2 (pt) 2008-02-21 2015-08-25 Actelion Pharmaceuticals Ltd Derivado de 2-aza-biciclo [2.2.1] heptano
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
JP2011522878A (ja) 2008-06-11 2011-08-04 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのテトラゾール化合物
WO2009153180A1 (en) 2008-06-16 2009-12-23 F. Hoffmann-La Roche Ag Heteroaromatic monoamides as orexinin receptor antagonists
US20110105514A1 (en) 2008-06-25 2011-05-05 Hamed Aissaoui 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds
CA2729985A1 (en) 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
CA2731403C (en) 2008-07-29 2013-11-05 F. Hoffmann-La Roche Ag Pyrrolidin-3-ylmethyl-amine as orexin antagonists
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010044054A1 (en) 2008-10-14 2010-04-22 Actelion Pharmaceuticals Ltd Phenethylamide derivatives and their heterocyclic analogues
CA2739915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CA2739927A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
AU2009307918A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,4-disubstituted pyrrolidine orexin receptor antagonists
JP2012506375A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換ピペリジンオレキシン受容体アンタゴニスト
WO2010048016A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
AU2009307916A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
WO2010051238A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
EP2350010B1 (en) 2008-10-30 2014-03-26 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
CA2741648A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
CA2745433A1 (en) 2008-12-02 2010-06-10 Glaxo Group Ltd. N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
JP2010155827A (ja) 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20100222396A1 (en) 2009-01-30 2010-09-02 Novartis Ag 4-aryl-butane-1,3-diamides
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
US20120101106A1 (en) 2009-07-09 2012-04-26 Mercer Swati P Tetrahydronapthyridine Orexin Receptor Antagonists
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
US8809380B2 (en) 2009-08-04 2014-08-19 Raqualia Pharma Inc. Picolinamide derivatives as TTX-S blockers
WO2011023585A1 (en) 2009-08-24 2011-03-03 Glaxo Group Limited Piperidine derivatives used as orexin antagonists
US20120149723A1 (en) 2009-08-24 2012-06-14 Romano Di Fabio 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder
WO2011050202A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
ES2585806T3 (es) 2009-10-23 2016-10-10 Janssen Pharmaceutica N.V. Octahidropirrolo [3,4-c] pirroles disustituidos como moduladores de receptores de orexina
EP2491034B1 (en) 2009-10-23 2013-12-18 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds as orexin receptor modulators
WO2011053522A1 (en) 2009-10-29 2011-05-05 Merck Sharp & Dohme Corp. Tertiary amide orexin receptor antagonists
US20120258957A1 (en) 2009-11-23 2012-10-11 Matilda Jane Bingham Heterocyclic derivatives
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
EP2516437B1 (en) 2009-12-21 2014-01-29 Novartis AG Disubstituted heteroaryl-fused pyridines
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
US20130281465A1 (en) 2010-12-17 2013-10-24 Taisho Pharmaceutical Co., Ltd. Pyrazole derivative
WO2012085852A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012110986A1 (en) 2011-02-18 2012-08-23 Actelion Pharmaceuticals Ltd Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
EP2708537A4 (en) 2011-05-10 2014-10-01 Taisho Pharmaceutical Co Ltd HETEROAROMATIC RING DERIVATIVE
JPWO2013005755A1 (ja) 2011-07-05 2015-02-23 大正製薬株式会社 メチルピペリジン誘導体
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013059163A1 (en) 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
WO2013062857A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Piperidinyl alkyne orexin receptor antagonists
WO2013062858A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
DK2776430T3 (en) 2011-11-08 2016-05-09 Actelion Pharmaceuticals Ltd 2- (1,2,3-triazol-2-yl) benzamide and 3- (1,2,3-triazol-2-yl) PICOLINAMIDDERIVATER AS orexin receptor antagonists
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
WO2013119639A1 (en) 2012-02-07 2013-08-15 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
WO2013123240A1 (en) 2012-02-17 2013-08-22 Eisai R&D Management Co., Ltd Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
ITMI20120322A1 (it) * 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
UY35993A (es) 2014-02-12 2015-08-31 Eolas Therapeutics Inc Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina

Similar Documents

Publication Publication Date Title
JP2008513516A5 (enExample)
CN105473581B (zh) 作为溴结构域抑制剂的新取代的双环化合物
JP2017533968A5 (enExample)
JP2019532079A5 (enExample)
JP2008513498A5 (enExample)
KR101585848B1 (ko) 관절염의 치료 방법
JP2018517752A5 (enExample)
JP2008513515A5 (enExample)
JP2018517746A5 (enExample)
JP2017531688A5 (enExample)
JP2013500267A5 (enExample)
JP2014513110A5 (enExample)
US20160000783A1 (en) Trk-INHIBITING COMPOUND
JP2011509309A5 (enExample)
JP2013540794A (ja) 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬
JP2015506382A5 (enExample)
RU2014136339A (ru) Замещенные пролины/пиперидины как антагонисты орексиновых рецепторов
JP2017095366A (ja) 新規ビアリールアミド誘導体
JP2019520344A5 (enExample)
JP2019511466A5 (enExample)
KR102544132B1 (ko) 항종양 활성을 갖는 화합물
JP5822079B2 (ja) 疼痛治療剤
TWI903404B (zh) 雜環化合物
JP2008511574A5 (enExample)
KR20080040692A (ko) 단백질 키나제 억제제로서의 2-아미노아릴 피리딘